Document is current
Any future updates will be listed below
-
Authors
Kangas, Brian D. https://orcid.org/0000-0002-4597-9801
Deshpande, Harshawardhan U.
Withey, Sarah L.
Spealman, Roger D.
Bergman, Jack
Kohut, Stephen J. https://orcid.org/0000-0002-6906-8818
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (R01-DA047575, R01-DA047575, R01-DA047575, R01-DA047575, R01-DA047575, R01-DA047575)
- License Information
-
More Information
Article History
Received: 10 July 2024
Revised: 14 October 2024
Accepted: 3 November 2024
First Online: 13 November 2024
Competing interests
: Over the past 3 years, BDK has had sponsored research agreements with BlackThorn Therapeutics, Compass Pathways, Delix Therapeutics, Engrail Therapeutics, Neurocrine Biosciences, and Takeda Pharmaceuticals. No funding from these entities was used to support the current work. All other authors have no conflicts of interest or relevant disclosures.
